Literature DB >> 35381385

Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data from a Large Tertiary Center.

Nathaniel A Cohen1, David Choi1, Tenzin Choden1, Noa Krugliak Cleveland1, Russell D Cohen1, David T Rubin2.   

Abstract

Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We describe the first report of the use of ozanimod in real-world clinical practice.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2022        PMID: 35381385     DOI: 10.1016/j.cgh.2022.03.035

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  1 in total

Review 1.  Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine.

Authors:  Arianna Dal Buono; Roberto Gabbiadini; Ludovico Alfarone; Virginia Solitano; Alessandro Repici; Stefania Vetrano; Antonino Spinelli; Alessandro Armuzzi
Journal:  Biomedicines       Date:  2022-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.